Jump to content

Malcolm Rowland

Add links
From Wikipedia, the free encyclopedia
(Redirected from Draft:Malcolm Rowland)

Malcolm Rowland
Rowland, 2021
Born
London, UK
NationalityEnglish
Known forPharmacy

Malcolm Rowland FBPhS[1] (born 5 August 1939, in London) is Emeritus Professor of Pharmacy, University of Manchester,[2] and adjunct professor, University of California San Francisco. His research in pharmacology, has been particularly in physiologically based pharmacokinetics (that deals with the movement in time of drugs and their metabolites within the body).[3] He has written several textbooks on the subject.

He studied Pharmacy at Chelsea College (now Kings College), an internal college of the University of London, gaining a B.Pharm (1961) and subsequently a Ph.D (1965).

Academic career

[edit]

Following his Ph.D. degree research into the pharmacokinetics of amphetamines,[4] he took up a postdoctoral research appointment in the laboratory of Sidney Riegelman, School of Pharmacy, University of California, San Francisco (1965-1967), studying the pharmacokinetics of aspirin, and then took up a faculty position there (1967–75). While at UCSF.[5] Rowland became a member of the joint Pharmacy-Medicine NIGMS funded program in Clinical Pharmacology, and moved his research from a prevailing descriptive approach to a more mechanistic, physiologically-based one,[6] including the clearance concept[7][8] that helped lay the foundations of modern pharmacokinetics. Together with Riegelman and Leslie Benet he founded the Journal of Pharmacokinetics and Biopharmaceutics (1973)[9] (renamed Journal of Pharmacokinetics and Pharmacodynamics, 2001), and was a senior editor of it until 2007.

In 1975 Rowland returned to the United Kingdom to take up a position of Professor of Pharmacy, University of Manchester where he extended his research on physiologically based pharmacokinetics[10][11] including development of an in silico method for predicting tissue distribution of drugs based on tissue composition and physicochemical properties.[12] In 1983 he founded Medeval,[13] undertaking early stage clinical evaluation of new medicines under development. Together with Brian Houston and Leon Aarons he established the Centre for Applied Pharmacokinetic Research (1996).[14] He has promoted the application of microdosing in clinical drug development.[15][16]

He headed the School of Pharmacy at Manchester on two occasions, 1988-1991 and 1998-2001, periods involving the move to clinical pharmacy and moving Pharmacy from the Faculty of Science and Engineering to the Faculty of Medicine, in recognition of the changing professional role of pharmacists from fabricator to health care advisor on medicines. Rowland has trained 90 Ph.D. students and scientists from a variety of disciplines. He also established ongoing annual postgraduate workshops in basic pharmacokinetics with Tomas Tozer (1977), and in advanced methods in pharmacokinetics and pharmacodynamics with Lewis Sheiner (1981).[17]

Rowland was president of EUFEPS (European Federation for Pharmaceutical Sciences, 1996-1999),[18] and a Vice-President of FIP (International Pharmaceutical Federation,2001-2009).[19]

Published works

[edit]

Rowland has published over 270 research articles in international peer-reviewed journals, and over 60 book chapters and conference reports. He co-authored with Thomas Tozer two standard textbooks: Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, now in its 5th edition, and Essentials of Pharmacokinetics and Pharmacodynamics.[20]

Honours and awards

[edit]

He received honorary degrees from University of Poitiers, France (D.Sc.1981), Uppsala University, Sweden (FarmDhc, 1989),[21] and Athens University, Greece ( D.Sc., 2011).[22] He was made Fellow, Academy of Medical Sciences (2001), Fellow, British Pharmacological Society (2012), and Honorary Fellow, American College of Clinical Pharmacology (2003).[23] He received the Scheele Award (Swedish Academy of Pharmaceutical Sciences, 1984),[24] the Distinguished Investigator Award (American College of Clinical Pharmacology, 2007), the New Safe Medicines Faster Award (EUFEPS, 2009), Research Achievement Award in Pharmacokinetics (American Association of Pharmaceutical Scientists, 1994),[25] the Sheiner-Beal Award in Pharmacometrics (American Society of Clinical Pharmacology and Therapeutics, 2012)[26] and the Ariens Award (Dutch Pharmacological Society, 2020)[27]., as well as the Harrison Memorial Medal (Royal Pharmaceutical Society of Great Britain, 1992)[28] and Host Madsen Medal (International Pharmaceutical Federation, 2011).[29]

Personal life

[edit]

Malcolm married Dawn Shane, in 1965. They have two daughters, and 5 grandchildren.[citation needed]

References

[edit]
  1. ^ Fellows bps.ac.uk [dead link]
  2. ^ "Search for people | The University of Manchester". personalpages.manchester.ac.uk.
  3. ^ "Distinguished Pharmaceutical Scientist: Malcolm Rowland (2006)". YouTube.
  4. ^ Rowland, M (1965). Chemical and biochemical studies with amphetamine (Thesis). OCLC 1006126238.
  5. ^ "1967–1978: The Riegelman Chairship · History of the Department of Bioengineering and Therapeutic Sciences".
  6. ^ Benowitz, Neal; Forsyth, Ralph P.; Melmon, Kenneth L.; Rowland, Malcolm (July 1974). "Lidocaine disposition kinetics in monkey and man; I. Prediction by a perfusion model". Clinical Pharmacology & Therapeutics. 16 (1part1): 87–98. doi:10.1002/cpt1974161part187. PMID 4210516. S2CID 32330285.
  7. ^ Rowland, Malcolm; Benet, Leslie Z.; Graham, Garry G. (April 1973). "Clearance concepts in pharmacokinetics". Journal of Pharmacokinetics and Biopharmaceutics. 1 (2): 123–136. doi:10.1007/BF01059626. PMID 4764426. S2CID 9361701.
  8. ^ Pang, K. Sandy; Rowland, Malcolm (December 1977). "Hepatic clearance of drugs. I. Theoretical considerations of a 'well-stirred' model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance". Journal of Pharmacokinetics and Biopharmaceutics. 5 (6): 625–653. doi:10.1007/BF01059688. PMID 599411. S2CID 28316323.
  9. ^ Bonate, Peter L. (February 2020). "On the shoulders of giants…". Journal of Pharmacokinetics and Pharmacodynamics. 47 (1): 1. doi:10.1007/s10928-020-09674-4. PMID 31960232. S2CID 210717345.
  10. ^ Roberts, Michael S.; Rowland, Malcolm (1 June 1986). "A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations". Journal of Pharmacokinetics and Biopharmaceutics. 14 (3): 227–260. doi:10.1007/BF01106706. PMID 3783446. S2CID 44671643.
  11. ^ Cheung, S Y A; Rodgers, T; Aarons, L; Gueorguieva, I; Dickinson, G L; Murby, S; Brown, C; Collins, B; Rowland, M (January 2018). "Whole body physiologically based modelling of β-blockers in the rat: events in tissues and plasma following an i.v. bolus dose: WBPBPK modelling of β-blockers in the rat". British Journal of Pharmacology. 175 (1): 67–83. doi:10.1111/bph.14071. PMC 5740248. PMID 29053169.
  12. ^ Rodgers, Trudy; Rowland, Malcolm (June 2006). "Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions". Journal of Pharmaceutical Sciences. 95 (6): 1238–1257. doi:10.1002/jps.20502. PMID 16639716.
  13. ^ "Drug development | the University of Manchester".
  14. ^ "Home". capkr.manchester.ac.uk.
  15. ^ Lappin, Graham; Shishikura, Yoko; Jochemsen, Roeline; Weaver, Richard John; Gesson, Charlotte; Brian Houston, J.; Oosterhuis, Berend; Bjerrum, Ole J.; Grynkiewicz, Grzegorz; Alder, Jane; Rowland, Malcolm; Garner, Colin (June 2011). "Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers". European Journal of Pharmaceutical Sciences. 43 (3): 141–150. doi:10.1016/j.ejps.2011.04.009. PMID 21540108.
  16. ^ Burt, Tal; Young, Graeme; Lee, Wooin; Kusuhara, Hiroyuki; Langer, Oliver; Rowland, Malcolm; Sugiyama, Yuichi (November 2020). "Phase 0/microdosing approaches: time for mainstream application in drug development?". Nature Reviews Drug Discovery. 19 (11): 801–818. doi:10.1038/s41573-020-0080-x. PMID 32901140. S2CID 221573443.
  17. ^ "Home". pkworkshops.com.
  18. ^ "History - Eufeps".
  19. ^ "Structure and statutes". www.fip.org.
  20. ^ Derendorf, Hartmut (January 2020). "Rowland and Tozer's Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, 5e".
  21. ^ "Honorary Doctors of the Faculty of Pharmacy - Uppsala University, Sweden".
  22. ^ "ΕΚΠΑ: Τμήμα Φαρμακευτικής - Επίτιμοι Διδάκτορες".
  23. ^ "Prior Recognition Award Winners | ACCP".
  24. ^ "Former Laurates".
  25. ^ "Past Award Recipients – AAPS Historical Awards" (PDF). AAPS. Retrieved 24 September 2023.
  26. ^ "Sheiner-Beal Pharmacometrics Award" (PDF). ascpt.org. Archived from the original (PDF) on 3 June 2021.
  27. ^ "Ariens Award – NVF".
  28. ^ "Hanbury and Harrison Medal winners announced | Royal Pharmaceutical Society | RPS".
  29. ^ "Awards". fip.org.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Malcolm_Rowland&oldid=1238557007"